Standout Papers
- Renal outcomes with telmisartan, ramipril, or both, in people at high vascular risk (the ONTARGET study): a multicentre, randomised, double-blind, controlled trial (2008)
- Effects of the angiotensin-receptor blocker telmisartan on cardiovascular events in high-risk patients intolerant to angiotensin-converting enzyme inhibitors: a randomised controlled trial (2008)
- Cardiovascular and Renal Outcomes with Efpeglenatide in Type 2 Diabetes (2021)
- Major Adverse Limb Events and Mortality in Patients With Peripheral Artery Disease (2018)
Immediate Impact
2 from Science/Nature 84 standout
Citing Papers
Mapping the effectiveness and risks of GLP-1 receptor agonists
2025 Standout
Effects of Semaglutide on Heart Failure Outcomes in Diabetes and Chronic Kidney Disease in the FLOW Trial
2024 Standout
Works of Leanne Dyal being referenced
Cardiovascular and Renal Outcomes with Efpeglenatide in Type 2 Diabetes
2021 Standout
Author Peers
| Author | Last Decade | Papers | Cites | |||
|---|---|---|---|---|---|---|
| Leanne Dyal | 1867 | 1262 | 635 | 24 | 3.1k | |
| Alain Bonnardeaux | 1200 | 979 | 350 | 39 | 2.9k | |
| A.Richard Christlieb | 1307 | 1743 | 549 | 50 | 3.7k | |
| Jan Menne | 1573 | 655 | 444 | 59 | 2.9k | |
| Xingyu Wang | 955 | 722 | 567 | 69 | 2.5k | |
| Tage Lysbo Svendsen | 1573 | 686 | 310 | 54 | 2.4k | |
| Steven L. Zelenkofske | 2865 | 645 | 620 | 29 | 4.0k | |
| Robert Segal | 2723 | 827 | 592 | 65 | 3.9k | |
| Vesta Lai | 724 | 1447 | 719 | 41 | 2.5k | |
| Mordchai Ravid | 1703 | 1391 | 485 | 93 | 3.7k | |
| Mónica Rupérez | 1738 | 844 | 421 | 29 | 4.1k |
All Works
Loading papers...